Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2024-01-10
Target enrollment:
Participant gender:
Summary
In order to further evaluate the efficacy of immunotherapy combined with antivascular therapy
in the real world, we used Serpluimab combined with Bevacizumab and platinum-based
chemotherapy in previously untreated EGFR/ALK-negative advanced non-squamous NSCLC patients,
to evaluate the efficacy and safety of this regimen.